Clinical trials: Osimertinib
Lung Cancer
Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small…
- Trial name
- ASTRIS (NCT02474355)
- Testing
- T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG
- Where
- 201 sites in Argentina, Australia and 14 more
- Volunteers
- 3,017 people
- Sponsor
- AstraZeneca
NSCLC
Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy
The T790M mutation is highly sensitive to osimertinib, which is approved in this setting following failure of gefitinib, erlotinib or afatinib.
- Trial name
- NCT04930133
- Testing
- Gilotrif
- Where
- South Korea
- Volunteers
- 737 people
- Sponsor
- Seoul St. Mary's Hospital
Non Small Cell Lung Cancer, EGFR Activating Mutation
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
IFCT-2202 ROSIE study aims to incorporate a broad-panel centralized NGS testing at baseline in all patients with completely resected NSCLC with common EGFR mutation after confirmation of an optimal preoperative extension…
- Conditions
- Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R
- Trial name
- ROSIE (NCT06053099)
- Testing
- Plasma ctDNA, FFPE blocks
- Where
- 36 sites in France
- Volunteers
- 300 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Nsclc
Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients
This is a Phase I study of repotrectinib in combination with osimertinib in patients with advanced or metastatic EGFR mutant non small cell lung cancer (NSCLC).
- Trial name
- TOTEM (NCT04772235)
- Testing
- Repotrectinib, Osimertinib
- Where
- 4 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Instituto Oncológico Dr Rosell
Non-small Cell Lung Cancer
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
- Trial name
- NCT04324164
- Testing
- Third-generation EGFR-TKI, EGFR-TKI
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Hunan Province Tumor Hospital
Non-Small Cell Lung Cancer
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
- Trial name
- NCT03122717
- Testing
- Gefitinib, Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dana-Farber Cancer Institute
Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor…
- Conditions
- Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT06538038
- Testing
- Osimertinib, Osimertinib + Chemotherapy
- Where
- 146 sites in United States
- Volunteers
- 200 people
- Sponsor
- PrECOG, LLC.
Grade II Glioma, Grade III Glioma
Implantable Microdevice In Primary Brain Tumors
This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in malignant brain tumors.
- Conditions
- Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma
- Trial name
- NCT04135807
- Testing
- Microdevice
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oliver Jonas
Non-small Cell Lung Cancer (NSCLC)
Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)
This will be a Phase II, open-label, single-arm, multicenter study of the efficacy and safety of osimertinib (80 mg orally once daily) in patients with LM associated with EGFRm+ NSCLC.
- Trial name
- BLOSSOM (NCT04563871)
- Testing
- 80mg Osimertinib
- Where
- 6 sites in South Korea
- Volunteers
- 73 people
- Sponsor
- Sehhoon Park
Non Small Cell Lung Cancer, EGFR Gene Mutation
Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.
This is a single-center, prospective, single-arm, phase II study of Osimertinib combined with Aspirin neoadjuvant therapy for resectable, EGFR mutated non-small cell lung cancer (NSCLC).
- Trial name
- NCT06018688
- Testing
- Osimertinib, Aspirin
- Volunteers
- 44 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non Small Cell Lung Cancer
Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
This is a multicenter, randomized, open-label, non-inferiority real world study. The study is designed to evaluate the efficacy and safety of Aumolertinib versus Osimertinib in the first-line treatment of patients with EGFR…
- Trial name
- ANOTHER (NCT06752408)
- Testing
- Aumolertinib, Osimertinib
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Peking Union Medical College Hospital
NSCLC
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
This is a Phase 1a/b, multicenter, open-label, dose escalation (1a) and dose expansion (1b) study. The purpose of this study is to measure safety, tolerability, and preliminary efficacy with the combination of tipifarnib with…
- Trial name
- NCT05693090
- Testing
- Tipifarnib, Osimertinib
- Where
- 2 sites in United States
- Sponsor
- Kura Oncology, Inc.
Non Small Cell Lung Cancer
Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02197247
- Testing
- Pharmacokinetic sampling - AZD9291, Rifampicin, AZD9291 tablet dosing
- Where
- 18 sites in United States, Netherlands and 4 more
- Volunteers
- 41 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive
This is a retrospective, multicenter and observational study of Osimertinib monotherapy treatment in Subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M mutation-positive who have received the…
- Trial name
- OSIREX (NCT03790397)
- Testing
- Osimertinib
- Where
- 31 sites in Spain
- Volunteers
- 169 people
- Sponsor
- Fundación GECP
Negative T790M Mutation and Met Amplification
Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors
To explore the safety and efficacy of Glumetinib combined with Osimertinib in the treatment of relapsed and metastatic non-small cell lung cancer (NSCLC) with failed first-generation or second-generation EGFR inhibitors, negative…
- Trial name
- NCT04338243
- Testing
- Glumetinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Metastatic Non Small Cell Lung Cancer
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
In this study, patients with metastatic non-small cell lung cancer that is EGFR-mutated, who have received at least 8 and not more than 12 weeks of treatment with osimertinib without demonstrating disease progression, will…
- Trial name
- NCT04743505
- Testing
- APL-101, Osimertinib
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Carcinoma, Non-Small-Cell Lung
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
A Multicountry, Multicenter, Non-interventional, Retrospective Study to determine Real-world treatment patterns and associated outcomes after FIRST LINE Osimertinib in patients with advanced and Metastatic NSCLC harboring…
- Trial name
- TREASURE (NCT06039683)
- Where
- 7 sites in Kuwait, Qatar and 2 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
ctDNA Guided Treatment of Early Resistance to Targeted Treatment
The current strategy is to test for treatment resistance at the time of radiological progression and design subsequent treatment based on the mechanism of resistance.
- Trial name
- TATIN (NCT04148066)
- Testing
- ctDNA blood sample
- Where
- 2 sites in Netherlands
- Volunteers
- 104 people
- Sponsor
- The Netherlands Cancer Institute
Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
This is a single-arm, multicenter, open-label, phase Ⅱ exploratory clinical study, which plans to enroll 74 treatment-naive patients with EGFR-sensitive mutations (exon 19 deletion, exon 21 L858R mutation) and symptomatic brain…
- Trial name
- HOPE-WBRT (NCT07505173)
- Testing
- Hippocampal-Sparing Whole-Brain Radiotherapy + Simultaneous Integrated Boost to Brain Metastases + O, Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-classic Mutated Lung Cancer
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Lung Cancer
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The aim of the study is to evaluate the efficacy and safety of SKB264 in combination with osimertinib as first-Line treatment for patients with epidermal growth factor receptor (EGFR) mutations, locally advanced or metastatic…
- Trial name
- NCT06670196
- Testing
- SKB264, Osimertinib
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.